Donoghue Forlines’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.63M | Buy |
67,585
+6,584
| +11% | +$172K | 0.42% | 92 |
|
|
2026
Q1 | $1.71M | Buy |
61,001
+3,338
| +6% | +$88.9K | 0.47% | 68 |
|
|
2025
Q4 | $1.44M | Sell |
57,663
-2,876
| -5% | -$72.5K | 0.44% | 97 |
|
|
2025
Q3 | $1.54M | Buy |
60,539
+371
| +0.6% | +$9.16K | 0.48% | 68 |
|
|
2025
Q2 | $1.46M | Buy |
60,168
+3,576
| +6% | +$83.4K | 0.42% | 82 |
|
|
2025
Q1 | $1.43M | Buy |
+56,592
| New | +$1.48M | 0.45% | 93 |
|
|
2023
Q4 | – | Sell |
-21,132
| Closed | -$701K | – | 249 |
|
|
2023
Q3 | $701K | Buy |
21,132
+11,042
| +109% | +$390K | 0.25% | 121 |
|
|
2023
Q2 | $370K | Sell |
10,090
-12,246
| -55% | -$477K | 0.12% | 197 |
|
|
2023
Q1 | $911K | Buy |
22,336
+2,640
| +13% | +$114K | 0.33% | 89 |
|
|
2022
Q4 | $1.01M | Sell |
19,696
-4,158
| -17% | -$199K | 0.36% | 86 |
|
|
2022
Q3 | $1.04M | Sell |
23,854
-33,988
| -59% | -$1.65M | 0.38% | 35 |
|
|
2022
Q2 | $3.03M | Sell |
57,842
-25,581
| -31% | -$1.3M | 0.79% | 16 |
|
|
2022
Q1 | $4.32M | Buy |
83,423
+33,034
| +66% | +$1.71M | 0.94% | 15 |
|
|
2021
Q4 | $2.98M | Sell |
50,389
-2,044
| -4% | -$101K | 0.5% | 30 |
|
|
2021
Q3 | $2.25M | Buy |
52,433
+21,925
| +72% | +$971K | 0.44% | 49 |
|
|
2021
Q2 | $1.2M | Sell |
30,508
-3,990
| -12% | -$155K | 0.22% | 102 |
|
|
2021
Q1 | $1.25M | Buy |
+34,498
| New | +$1.22M | 0.24% | 104 |
|
|
2020
Q4 | – | Sell |
-34,436
| Closed | -$1.2M | – | 283 |
|
|
2020
Q3 | $1.2M | Buy |
+34,436
| New | +$1.21M | 0.33% | 81 |
|
|
2020
Q2 | – | Sell |
-24,441
| Closed | -$757K | – | 93 |
|
|
2020
Q1 | $757K | Sell |
24,441
-65,654
| -73% | -$2.24M | 0.17% | 26 |
|
|
2019
Q4 | $3.35M | Sell |
90,095
-35,354
| -28% | -$1.26M | 0.52% | 42 |
|
|
2019
Q3 | $4.28M | Sell |
125,449
-31,760
| -20% | -$1.15M | 0.61% | 50 |
|
|
2019
Q2 | $6.46M | Buy |
+157,209
| New | +$6.24M | 0.76% | 52 |
|
|
2018
Q4 | – | Sell |
-330,558
| Closed | -$13.8M | – | 117 |
|
|
2018
Q3 | $13.8M | Sell |
330,558
-133,480
| -29% | -$5.14M | 1.08% | 30 |
|
|
2018
Q2 | $16M | Sell |
464,038
-48,917
| -10% | -$1.67M | 1.32% | 35 |
|
|
2018
Q1 | $17.3M | Sell |
512,955
-13,233
| -3% | -$455K | 1.5% | 23 |
|
|
2017
Q4 | $18.1M | Buy |
526,188
+26,759
| +5% | +$912K | 1.37% | 30 |
|
|
2017
Q3 | $16.9M | Sell |
499,429
-15,234
| -3% | -$490K | 1.78% | 24 |
|
|
2017
Q2 | $16.4M | Buy |
+514,663
| New | +$16.2M | 1.86% | 17 |
|
Other funds holding PFE
Donoghue Forlines's PFE Position: Q2 2026 in Review
Donoghue Forlines increased its Pfizer (PFE) stake by 11% in Q2 2026, buying an estimated $172K and bringing the position to 67,585 shares worth $1.63M. The position accounts for 0.42% of the portfolio, ranked #92.
Donoghue Forlines first reported a position in PFE in Q2 2017 and has held it in 28 quarters since. The position peaked at $18.1M in Q4 2017. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Donoghue Forlines held 67,585 shares of Pfizer worth $1.63M as of Q2 2026.
- Donoghue Forlines bought 6,584 Pfizer shares in Q2 2026, an estimated $172K.
- Pfizer made up 0.42% of Donoghue Forlines's portfolio in Q2 2026, its #92 holding.
- Donoghue Forlines first reported a position in Pfizer in Q2 2017 and has held it in 28 quarters since.
- Donoghue Forlines's Pfizer position peaked at $18.1M in Q4 2017.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Donoghue Forlines's 13F filing for Q2 2026, filed 7 Aug 2026.